

Aiming to Be a Business that Improves People's Health and Makes Them Smile -At a Glance-

Nippon Shinyaku's two businesses are Pharmaceuticals and Functional Food.

In the Pharmaceuticals Business, the Company aims to deliver high-quality and highly unique products to as many patients as possible, as quickly as possible.

In the Functional Food Business, it aims to continually provide high-value-added products that meet market needs and realize healthy and happy lives for people.

Pharmaceuticals

Strengths

In-house drug
discovery

In-licensing

PLCM

Intractable and Rare Diseases

- Viltepso
- Uptravi
- Fintepla
- Adcirca

Urology

- Zolutia
- Cialis

Hematology

- Vyxeos
- Vidaza
- Gazyva
- Defitelio

Gynecology

- MonoVer

Focus areas and main products

B2B Business

- Protein Preparations
- Preservatives
- Health Food Ingredients

B2C Business

- Sports Supplements
- WINZONE series

- Aging Care Supplements
- Kiwami Select Collagen

Functional Food

Strengths

Fundamental
Research and
In-house

In-licensing

PLCM

Revenue



¥148.255 billion

Increase of 2.8% year on year ↑


Profit attributable to owners of parent



¥25.851 billion

Increase of 13.3% year on year ↑

Revenue by segment/Revenue ratio



EPS

¥383.82

Increase of 13.3% year on year ↑

CO₂ emissions (Scope 1, 2)



7,283 t-CO₂

Decrease of 20.7 % year on year ↓

Uptake rate for childcare leave (male)



70.8%

Increase of 1.5pt year on year ↑

Operating profit



¥33.295 billion

Increase of 10.8% year on year ↑


Research and development expenses



¥31.676 billion

Increase of 31.2% year on year ↑

Breakdown of revenue by region/Revenue composition ratio



ROE

12.4%

Increase of 0.3pt year on year ↑

Ratio of female managers



13.4%

Increase of 0.1pt year on year ↑

Gender pay gap



78.8%

Decrease of 0.8pt year on year ↓